Born in Hungary, Galo (46) has extensive management experience in the dental and consumer goods industries and has lived in Switzerland since 2011. His career includes senior positions at Ivoclar and Electronic Arts (EA), most recently with global responsibility for commercialization, including market launch and marketing strategies.
Portfolio expansion and diversification in over 40 countries
With Istvan Galo, Geistlich gains a strategically savvy expert who will drive the company's growth and diversification strategy in the markets. This focuses on tapping into emerging markets and targeting new customer segments. In order to meet the diverse needs of the market, Geistlich will expand its portfolio with 20 new products in over 40 countries by the end of 2026. This includes the introduction of new technologies and product variants such as Geistlich Bio-Gide® Forte and Geistlich Bio-Oss® Flow, as well as the launch of Geistlich SwissGraft® X and Geistlich SwissMembrane® X for emerging markets. By 2035, Geistlich aims to improve the quality of life for even more people through high-quality dental regeneration.
Diego Gabathuler, CEO of Geistlich Pharma AG, says: “Our strategy not only strengthens our leading position in existing markets, but also opens up access to reliable regeneration for additional patient groups worldwide. With Istvan Galo on our team, we are well equipped to achieve these ambitious goals.”